The Icos Alumni: Where Are They Now?

11/18/09Follow @xconomy

(Page 6 of 9)

Abby Kliphardt, production chemist, Bio-Rad Laboratories

Joshua Klocke, associate scientist IV, MDS Pharma Services

Byron Kneller, senior staff scientist, CMC Icos

Gabrielle Kolakowski, associate scientist, Array Biopharma

Sandy Kopponol, city council member, city of Lake Forest Park

Yvonne Lai, professor of biology, Indiana University

Keith Laycock, network analyst, City of Redmond

Sam Lee, president, CoCrystal Discovery

Dina Leviten, scientist, Ikaria

Michael Libby, assistant director of quality control, Irix Pharmaceuticals

Marykay Ligocki, research scientist

Mong-Wu Lin, quality control associate, Dharma Therapeutics

Brian Lipsky, senior associate research scientist, Amgen

Mila Lobanova, senior director of finance, ZymoGenetics

Christine Loh, associate director, Sirtris Pharmaceuticals

Kate Loughney, medical and scientific writing

Andrew Lover, graduate student researcher, National University of Singapore

Mark Lupher, senior vice president of drug discovery, Promedior

Mack Mabry, senior director, Trubion Pharmaceuticals

Linda MacKeen, director of medical writing, Seattle Genetics

Patricia Magnafichi, procurement manager, Genentech

Benjamin Maier, quality assurance senior specialist, CMC Icos

Linda Mangone, director of organization development and learning, Regence Blue Cross/BlueShield

Timothy Martins, co-director Quellos High Throughput Screening Core, Institute for Stem Cell and Regenerative Medicine, University of Washington

Mari Maurer, director of clinical operations, BioMarin Pharmaceutical [Added 12/30/09]

Kim Nordstrom McCaw, biotechnology professional

David McElligott, vice president of research and development, Mirina

William McFee, scientist, Seattle Genetics

David Meyer, senior research associate, Seattle Genetics

Greg Miller, scientist, Bayer Healthcare … Next Page »

Single Page Currently on Page: 1 2 3 4 5 6 7 8 9 previous page

By posting a comment, you agree to our terms and conditions.

  • http://www.northcoastbio.com Johnny T. Stine

    I actually loved our logo – very simple, but it just looked like fun.
    When George R. was recently asked by a reporter from an Everett newspaper about building Icos into a company like Amgen….he replied “…..why would I stop there?”. With a leader like that, like George, one who inspires with energetic goals such as that mentioned – we could’ve done it. We had the tools and the ability to do just that. We had great people who’ve all proven themselves in places before and afterward…….but imagine what we could’ve done behind the hopes of a great leader like George who set that tone….a CEO who knew all of our names, someone who would talk to you like you were a valued asset, a guy that empowered us via ownership. Imagine what we could’ve done…..because that’s all we’re left to do.

    By the way- Luke – I prefer Icosanoids – a play on the word eicosanoid since we were primarily an inflammation company. :-)

  • http://www.xconomy.com/author/ltimmerman/ Luke Timmerman

    Johnny—Unfortunately, I never really got to know George very well because he had already left Icos by the time I started covering the company in 2001. But I made a point of meeting him at his home once a couple years ago when I was based in San Francisco. He wasn’t in great health, but he was still sharp and very much curious about the latest happenings in biotech.

    I haven’t heard the term Icosanoids from eicosanoid, but that made me laugh this morning. It sounds like something from Star Trek. Anybody know if this was also the inspiration for the term “Immunoids” for people who used to work at Immunex?

  • http://www.BiotechStockResearch.com David Miller

    Nice work, Luke. Goes to prove that even though we might lose companies through acquisition we’d really rather keep, it’s not like everything connected with the company disappears. By my eye, the “loss” of Icos created at least a half-dozen new companies and significantly strengthened a dozen or more startups. A nice silver lining.

  • Abby Kliphardt

    Nice article…good to see where my co-workers have ended. I loved my time at ICOS and will always lament the loss of a great company that was a real family….

  • Pingback: The Icos Impact: What to Expect Next Week | Xconomy